PerpEquities

Equity · Healthcare

Summit Therapeutics Inc. (SMMT) perpetual futures

Summit Therapeutics Inc. is a biopharmaceutical firm developing treatments for infectious diseases, focusing on Clostridioides difficile infection and multidrug-resistant bacteria.

$9.94Market closed until the venue's next session · last quote Nov 20, 20:59 UTCNASDAQ closed
Open in terminal

Price chart

Interactive TradingView chart

TradingView symbol NASDAQ:SMMT

Loads TradingView's third-party widget (about 1 MB) on demand.

Auto: underlying reference priceOpen in TradingView

Trading data

Perpetual market activity

0/1 live markets
Venues
0
Live markets
0/1
24h volume
-
Open interest
-
Best liquidity
-
Tightest spread
-
Highest volume
-
Settlement mix
USDT · 1/1
Perp/spot vol.
-
Spot performance
1D-5.87%
5D-21.72%
1M-36.01%
6M-40.13%
YTD-43.11%
1Y-44.23%

Venue matrix

1 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
BingXTradeSMMT-USDTWatchlist------USDT-
Best venues for this underlying

Best liquidity

-
No live data-

Tightest spread

-
No live data-

Highest volume

-
No live data-

Company financials

Financials at a glance

Last report Q3 '26 · filed 2026-11-04 · next report 2027-02-22 · Updated 2h ago
All financials →

Valuation & key figures

Market cap
$7.96B
Updated 2h ago
Revenue
$0
Trailing 12 months
Revenue growth
–
FY2026 consensus
Profit margin
–
Net income / revenue, TTM
P/E
No P/E
Loss in the last twelve months
P/S
–
Price / sales, TTM
Peer P/E
23.4×
Similar listed perps
EV / EBITDA
-9.4×
TTM
Free cash flow
-$527M
Trailing 12 months
Net income
-$833M
Trailing 12 months
Revenue estimate
$2.24M
FY2026 consensus
Earnings
2027-02-22
Revenue est. $2.8M · Updated 2h ago
Dividend
–
No dividend
Revenue (TTM)$0– vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)–– vs a year agoOperating income -$855M
Net income (TTM)-$833M– vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)-$527M– vs a year agoCapex $1.73M
Diluted EPS (TTM)-$1.07– vs a year agoSum of the last 4 quarters
Net cash$610M– vs a year agoCash + short-term investments - debt
  • Last report (2026-11-04): revenue n/a, EPS beat by 7.7%Revenue – vs $111K expected (–); EPS -$0.26 vs -$0.28 (+7.7%).
  • Net cash $610MCash + short-term investments $630M, debt incl. leases $20M.

Revenue, operating income and growth

quarterly
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates · all 167 lines Summit Therapeutics Inc. reported to the SEC

Next catalyst

Catalysts

Earnings
2027-02-22
Revenue est. $2.8M · Updated 2h ago

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 2026-1.07$2.2M-95%8
FY 2027-1.02$41.8M+1,766%8
FY 2028-0.67$521.3M+1,148%7
FY 20290.11$1.7B+228%2
FY 20301.49$3.9B+127%4
Q3 2026-0.28$111.1K-7
Source: FMP · Consensus

Company events

6
2027-03-18EarningsActual - / Estimate -0.314-
2027-02-22EarningsActual - / Estimate -0.34-
2026-11-04EarningsActual -0.26 / Estimate -0.282Beat
2026-07-23EarningsActual -0.28 / Estimate -0.274Miss
2026-04-30EarningsActual -0.24 / Estimate -0.33Beat
2026-02-23EarningsActual -0.29 / Estimate -0.103Miss

Peer comparison

Similar listed perps

Company data

Company intelligence

Updated: Nov 22, 2026, 10:39 AM UTC

Company profile

Sector
Healthcare
Industry
Biotechnology
Chief executive
Robert W. Duggan
Employees
265
IPO date
Mar 5, 2015
Country
US
Exchange
NASDAQ Global Market
Website
Altman Z-scorei42.39
Piotroski scorei2/9
Overall ratingiC
Owner earningsi-$167.78M-$0.22 per share
ESG risk ratingiBIndustry rank: 285/724

Rating factors

Return on equityi
1/5
Return on assetsi
1/5
Debt to equityi
4/5
Price to earningsi
1/5
Price to booki
1/5
Market cap history
$7.94B-19.8%Aug 2026 – Nov 2026
$7.94B$11.14B$14.33BHigh: $14.33B · 2026-09-14Latest: $7.94B · 2026-11-20Aug 2026Sep 2026Oct 2026Nov 2026
Latest: $7.94B · 2026-11-20High: $14.33B · 2026-09-14Low: $7.94B · 2026-11-20
Largest fund holders
FundWeightShares held
XBI1.27%7.6M
VTI0%3.7M
VB0.02%2.7M
FDGRX0.04%2M
VXF0.03%1.8M
VBR0.03%1.7M
IBB0.17%1M
FBIOX0.24%803.5K
NIW0.06%773.3K
IWP0.07%769.7K
BTEC.L0.96%629.6K
FSPHX0.17%602.1K

Analyst track record

How the analysts covering SMMT have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings121261
Analysts2027
Buy / hold / sell70 / 48 / 3194 / 53 / 14
Upgrades / downgrades / initiations3 / 3 / 14 / 4 / 19
Price targets hit / missed3 / 93 (3%)8 / 192 (4%)
Avg. return after a rating (TipRanks)-56.4%-57.4%
Best / worst call+27.4% / -92.0%+51.0% / -92.0%

After buy calls on this stock: median 21-day move -1.2% vs S&P 500 -2.0% (n = 182)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Bradley CaninoGuggenheim55% hit rate on this stock · 11 targets measuredBuytarget $38.00Jul 23, 2026
  2. Yigal NochomovitzCiti42% hit rate on this stock · 12 targets measuredBuytarget $42.00Nov 16, 2026
  3. Cory KasimovEvercore ISI25% hit rate on this stock · 8 targets measuredBuytarget $34.00Nov 5, 2026

Latest ratings

DateAnalystCallTarget
Nov 18, 2026Daina GrayboschLeerink PartnersNov 18, 2026HoldMaintained–↗
Nov 18, 2026Jeffrey WalchBernsteinNov 18, 2026SellDowngraded$8.30↗
Nov 16, 2026Dara AzarStifel NicolausNov 16, 2026BuyMaintained$37.00↗
Nov 16, 2026Kelsey GoodwinPiper SandlerNov 16, 2026HoldMaintained$16.00↗
Nov 16, 2026Mitchell KapoorH.C. WainwrightNov 16, 2026HoldReiterated–↗
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$10.00$15.00$20.00$25.00$30.00$35.00$40.00Dec 25 · Buy 13 · Hold 3 · Sell 2Dec 25Jan 26 · Buy 11 · Hold 3 · Sell 2Feb 26 · Buy 11 · Hold 3 · Sell 2Feb 26Mar 26 · Buy 10 · Hold 4 · Sell 1Apr 26 · Buy 11 · Hold 4 · Sell 0Apr 26May 26 · Buy 9 · Hold 4 · Sell 0Jun 26 · Buy 9 · Hold 4 · Sell 1Jun 26Jul 26 · Buy 10 · Hold 4 · Sell 1Aug 26 · Buy 10 · Hold 6 · Sell 0Aug 26Sep 26 · Buy 12 · Hold 6 · Sell 0Oct 26 · Buy 11 · Hold 6 · Sell 0Oct 26Nov 26 · Buy 11 · Hold 6 · Sell 1Dec 25 · avg. target $39.35Jan 26 · avg. target $39.35Feb 26 · avg. target $30.17Mar 26 · avg. target $29.45Apr 26 · avg. target $31.54May 26 · avg. target $31.55Jun 26 · avg. target $29.73Jul 26 · avg. target $28.98Aug 26 · avg. target $28.99Sep 26 · avg. target $28.53Oct 26 · avg. target $28.66Nov 26 · avg. target $28.79Dec 25 · month-end close $17.49Jan 26 · month-end close $14.48Feb 26 · month-end close $16.59Mar 26 · month-end close $18.96Apr 26 · month-end close $21.46May 26 · month-end close $17.54Jun 26 · month-end close $14.57Jul 26 · month-end close $13.02Aug 26 · month-end close $13.62Sep 26 · month-end close $16.91Oct 26 · month-end close $16.03Nov 26 · month-end close $9.95

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data · computed Nov 20, 2026 · 121 ratings

Embed this asset

SMMT perpetuals · perpequities.comSMMT perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/smmt-perp"><img src="https://perpequities.com/badge/smmt-perp.svg" width="240" height="64" alt="SMMT perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of SMMT perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for SMMT — one email every Sunday.

Watchlist and alerts

Price and funding alerts for SMMT, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X